

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 10490

Title: Bevacizumab maintenance in metastatic colorectal cancer: how long? A case report.

Reviewer code: 00068472

Science editor: Ling-Ling Wen

Date sent for review: 2014-04-07 19:23

Date reviewed: 2014-04-28 02:13

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

General The authors describe a case of an old metastatic colorectal cancer patient receiving capecitabine, oxaliplatin and bevacizumab, who obtained a complete response after twelve months of treatment and kept on receiving bevacizumab as maintenance regimen for more than three years. The English language should be improved. **Specific comments** ? The maintenance therapy in non-progressive patients following approx. six months of chemotherapy and/or biological drugs is open to debate both for treatment duration and type of drug regimen. The Authors should spend more time to discuss this issue. ? The effectiveness and tolerability are the most important open questions of long-term therapy. ? They should explain the clear-cut indication of long-term therapy in this specific case. ? Prospective, randomized controlled trials are needed to clarify the real of benefit and cost-effectiveness of such a prolonged treatment. ? The list of References should be completed.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 10490

Title: Bevacizumab maintenance in metastatic colorectal cancer: how long? A case report.

Reviewer code: 00001114

Science editor: Ling-Ling Wen

Date sent for review: 2014-04-07 19:23

Date reviewed: 2014-04-28 22:24

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

I think this case report is a quite rare and clinically interesting. I have the following comments - 1) This case with metastatic colon cancer is a rare and interesting because of obtaining complete response by first line chemotherapy with Bev and then BEV maintenance. Therefore I think the author should show the specific details of this case. For example, pathological images of the primary lesion, expression of the EGFR or KRAS status.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 10490

Title: Bevacizumab maintenance in metastatic colorectal cancer: how long? A case report.

Reviewer code: 00057100

Science editor: Ling-Ling Wen

Date sent for review: 2014-04-07 19:23

Date reviewed: 2014-04-29 10:10

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Dear Editor: I have read with much interest the manuscript entitled "Bevacizumab maintenance in metastatic colorectal cancer: how long? A case report" by De Stefano Alfonso and coworkers. It is a very interested topic for physicians of multiple specialties such as Internal Medicine, Oncology, Surgery, Family Medicine. The manuscript is very well written. It can be published in the WJCC as it is.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 10490

Title: Bevacizumab maintenance in metastatic colorectal cancer: how long? A case report.

Reviewer code: 02773843

Science editor: Ling-Ling Wen

Date sent for review: 2014-04-07 19:23

Date reviewed: 2014-04-30 01:24

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

In manuscript "Bevacizumab maintenance in metastatic colorectal cancer: how long? A case report", the authors reported a case of an old patient received a three-year treatment with Bevacizumab for metastatic colorectal cancer. Due to toxicity and side effects, cancer patients usually take discontinuous chemotherapy during the whole treatment. How long does one anti-cancer drug could be continuously used on one patient is still an exploration trial. Although different patient has different response to the same drug, more cases were reported and more experience will obtained on cancer therapy. So the experience of the tolerability of such prolonged treatment will offer a reference for other similar patients. There are some grammar errors in the manuscript. The authors should check the manuscript very carefully before they submitted it.